ELOVL2-AS1 suppresses tamoxifen resistance by sponging miR-1233-3p in breast cancer

References

• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–13. doi: 10.1038/nrc2167
   PubMed Web of Science ®Google Scholar
• Li Y, Song Y, Lang R, et al. Retrospective study of malignant phyllodes tumors of the breast: younger age, prior fibroadenoma surgery, malignant heterologous elements and surgical margins may predict recurrence. Breast. 2021;57:62–70. doi: 10.1016/j.breast.2021.03.001
   PubMedGoogle Scholar
• Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–1846. doi: 10.1056/NEJMoa1701830
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423–438. doi: 10.1200/JCO.18.01160
   PubMed Web of Science ®Google Scholar
• Gulko B, Hubisz MJ, Gronau I, et al. A method for calculating probabilities of fitness consequences for point mutations across the human genome. Nat Genet. 2015;47(3):276–283. doi: 10.1038/ng.3196
   PubMed Web of Science ®Google Scholar
• Fagan DH, Uselman RR, Sachdev D, et al. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res. 2012;72(13):3372–3380. doi: 10.1158/0008-5472.CAN-12-0684
   PubMed Web of Science ®Google Scholar
• Ikeda K, Horie-Inoue K, Ueno T, et al. miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. Sci Rep. 2015;5(1):13170. doi: 10.1038/srep13170
   PubMed Web of Science ®Google Scholar
• Siegfried JM, Lin Y, Diergaarde B, et al. Expression of PAM50 genes in lung cancer: evidence that interactions between hormone receptors and HER2/HER3 contribute to poor outcome. Neoplasia. 2015;17(11):817–825. doi: 10.1016/j.neo.2015.11.002
   PubMed Web of Science ®Google Scholar
• Castro MA, de Santiago I, Campbell TM, et al. Regulators of genetic risk of breast cancer identified by integrative network analysis. Nat Genet. 2016;48(1):12–21. doi: 10.1038/ng.3458
   PubMed Web of Science ®Google Scholar
• Fox EM, Kuba MG, Miller TW, et al. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res. 2013;15(4):R55. doi: 10.1186/bcr3449
   PubMed Web of Science ®Google Scholar
• Redmond AM, Byrne C, Bane FT, et al. Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells. Oncogene. 2015;34(29):3871–3880. doi: 10.1038/onc.2014.323
   PubMed Web of Science ®Google Scholar
• Moradi F, Mohajerani F, Sadeghizadeh M. CCAT2 knockdown inhibits cell growth, and migration and promotes apoptosis through regulating the hsa-mir-145-5p/AKT3/mTOR axis in tamoxifen-resistant MCF7 cells. Life Sci. 2022;311:121183. doi: 10.1016/j.lfs.2022.121183
   PubMed Web of Science ®Google Scholar
• Tian Y, Chen ZH, Wu P, et al. MIR497HG-Derived miR-195 and miR-497 mediate tamoxifen resistance via PI3K/AKT signaling in breast cancer. Adv Sci. 2023;10(12):e2204819. doi: 10.1002/advs.202204819
   Web of Science ®Google Scholar
• Ouyang YX, Feng J, Wang Z, et al. miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα. Mol Biomed. 2021;2(1):20. doi: 10.1186/s43556-021-00045-0
   PubMedGoogle Scholar
• Yu X, Li R, Shi W, et al. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Biomed Pharmacother. 2016;77:37–44. doi: 10.1016/j.biopha.2015.11.005
   PubMed Web of Science ®Google Scholar
• Xue X, Yang YA, Zhang A, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2016;35(21):2746–2755. doi: 10.1038/onc.2015.340
   PubMed Web of Science ®Google Scholar
• Huang NS, Chi YY, Xue JY, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer. Oncotarget. 2016;7(25):37957–37965. doi: 10.18632/oncotarget.9364
   PubMedGoogle Scholar
• Lan WG, Xu DH, Xu C, et al. Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol Rep. 2016;36(1):263–270. doi: 10.3892/or.2016.4771
   PubMed Web of Science ®Google Scholar
• Li Z, Yu D, Li H, et al. Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. Int J Oncol. 2019;54:1033–1042. doi: 10.3892/ijo.2019.4679
   PubMed Web of Science ®Google Scholar
• Jeong D, Ham J, Kim HW, et al. ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer. Am J Cancer Res. 2021;11:2568–2589.
   PubMed Web of Science ®Google Scholar
• Kim HW, Jeong D, Ham J, et al. ZNRD1 and its antisense long noncoding RNA ZNRD1-AS1 are oppositely regulated by cold atmospheric plasma in breast cancer cells. Oxid Med Cell Longev. 2020;2020:9490567. doi: 10.1155/2020/9490567
   PubMed Web of Science ®Google Scholar
• Lee S, Lee H, Jeong D, et al. Cold atmospheric plasma restores tamoxifen sensitivity in resistant MCF-7 breast cancer cell. Free Radic Biol Med. 2017;110:280–290. doi: 10.1016/j.freeradbiomed.2017.06.017
   PubMed Web of Science ®Google Scholar
• Lee S, Park S, Lee H, et al. ChIP-seq analysis reveals alteration of H3K4 trimethylation occupancy in cancer-related genes by cold atmospheric plasma. Free Radic Biol Med. 2018;126:133–141. doi: 10.1016/j.freeradbiomed.2018.08.004
   PubMed Web of Science ®Google Scholar
• Kim JH, Kang S, Kim TW, et al. Expression profiling after induction of demethylation in MCF-7 breast cancer cells identifies involvement of TNF-α mediated cancer pathways. Mol Cells. 2012;33(2):127–133. doi: 10.1007/s10059-012-2182-8
   PubMed Web of Science ®Google Scholar
• Lu M, Wu Y, Zeng B, et al. CircEHMT1 inhibits metastatic potential of breast cancer cells by modulating miR-1233-3p/KLF4/MMP2 axis. Biochem Biophys Res Commun. 2020;526(2):306–313. doi: 10.1016/j.bbrc.2020.03.084
   PubMed Web of Science ®Google Scholar
• Zhu M, Zhang J, Li G, et al. ELOVL2-AS1 inhibits migration of triple negative breast cancer. PeerJ. 2022;10:e13264. doi: 10.7717/peerj.13264
   PubMed Web of Science ®Google Scholar
• Mangiavacchi A, Morelli G, Orlando V. Behind the scenes: how RNA orchestrates the epigenetic regulation of gene expression. Front Cell Dev Biol. 2023;11:1123975. doi: 10.3389/fcell.2023.1123975
   PubMed Web of Science ®Google Scholar
• Faghihi MA, Wahlestedt C. Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol. 2009;10(9):637–643. doi: 10.1038/nrm2738
   PubMed Web of Science ®Google Scholar
• Lee S, Kopp F, Chang TC, et al. Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins. Cell. 2016;164(1–2):69–80. doi: 10.1016/j.cell.2015.12.017
   PubMed Web of Science ®Google Scholar
• Liu YR, Jiang YZ, Xu XE, et al. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. Clin Cancer Res. 2016;22(7):1653–1662. doi: 10.1158/1078-0432.CCR-15-1555
   PubMed Web of Science ®Google Scholar
• Khorkova O, Stahl J, Joji A, et al. Natural antisense transcripts as drug targets. Front Mol Biosci. 2022;9:978375. doi: 10.3389/fmolb.2022.978375
   PubMed Web of Science ®Google Scholar
• Ren L, Zhou H, Lei L, et al. Long non-coding RNA FOXD3 antisense RNA 1 augments anti-estrogen resistance in breast cancer cells through the microRNA-363/trefoil factor 1/phosphatidylinositol 3-kinase/protein kinase B axis. Bioengineered. 2021;12(1):5266–5278. doi: 10.1080/21655979.2021.1962694
   PubMed Web of Science ®Google Scholar
• Feng J, Wen T, Li Z, et al. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance. Aging. 2020;12(20):20658–20683. doi: 10.18632/aging.103966
   PubMedGoogle Scholar
• Liu Y, Li M, Yu H, et al. lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR‑125a‑5p. Int J Mol Med. 2020;45:497–509. doi: 10.3892/ijmm.2019.4428
   PubMed Web of Science ®Google Scholar
• Xu W, Zhou B, Wu J, et al. Circular RNA hsa-circ-0007766 modulates the progression of gastric carcinoma via miR-1233-3p/GDF15 axis. Int J Med Sci. 2020;17(11):1569–1583. doi: 10.7150/ijms.46261
   PubMed Web of Science ®Google Scholar
• Ma W, Zhao P, Zang L, et al. CircTP53 promotes the proliferation of thyroid cancer via targeting miR-1233-3p/MDM2 axis. J Endocrinol Invest. 2021;44(2):353–362. doi: 10.1007/s40618-020-01317-2
   PubMed Web of Science ®Google Scholar
• Wang Y, Zang RK, Du YN. HSA_CIRC_0004050 on proliferation and apoptosis of A549 cells through ERK/JNK signaling pathway. J Biol Regul Homeost Agents. 2020;34(6):2037–2047. doi: 10.23812/20-543-A
   PubMed Web of Science ®Google Scholar
• He DX, Gu XT, Li YR, et al. Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer. FEBS J. 2014;281(20):4718–4730. doi: 10.1111/febs.13012
   PubMed Web of Science ®Google Scholar
• Ebert K, Mattes J, Kunzke T, et al. MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells. PLoS One. 2019;14(9):e0223225. doi: 10.1371/journal.pone.0223225
   PubMed Web of Science ®Google Scholar
• Shattuck DL, Miller JK, Carraway KL, et al. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008;68(5):1471–1477. doi: 10.1158/0008-5472.CAN-07-5962
   PubMed Web of Science ®Google Scholar
• Ibadurrahman W, Hanif N, Hermawan A. Functional network analysis of p85 and PI3K as potential gene targets and mechanism of oleanolic acid in overcoming breast cancer resistance to tamoxifen. J Genet Eng Biotechnol. 2022;20(1):66. doi: 10.1186/s43141-022-00341-4
   PubMed Web of Science ®Google Scholar